250 related articles for article (PubMed ID: 27497815)
1. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract][Full Text] [Related]
3. Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source.
Ovejero D; Michel Z; Cataisson C; Saikali A; Galisteo R; Yuspa SH; Collins MT; de Castro LF
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36943390
[TBL] [Abstract][Full Text] [Related]
4. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.
Lim YH; Ovejero D; Sugarman JS; Deklotz CM; Maruri A; Eichenfield LF; Kelley PK; Jüppner H; Gottschalk M; Tifft CJ; Gafni RI; Boyce AM; Cowen EW; Bhattacharyya N; Guthrie LC; Gahl WA; Golas G; Loring EC; Overton JD; Mane SM; Lifton RP; Levy ML; Collins MT; Choate KA
Hum Mol Genet; 2014 Jan; 23(2):397-407. PubMed ID: 24006476
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome.
Carli D; Cardaropoli S; Tessaris D; Coppo P; La Selva R; Cesario C; Lepri FR; Pullano V; Palumbo M; Ramenghi U; Brusco A; Medico E; De Sanctis L; Ferrero GB; Mussa A
Genes Chromosomes Cancer; 2022 Dec; 61(12):740-746. PubMed ID: 35999193
[TBL] [Abstract][Full Text] [Related]
7. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
8. Keratinocytic epidermal nevi associated with localized fibro-osseous lesions without hypophosphatemia.
Mestach L; Polubothu S; Calder A; Denayer E; Gholam K; Legius E; Levtchenko E; Van Laethem A; Brems H; Kinsler VA; Morren MA
Pediatr Dermatol; 2020 Sep; 37(5):890-895. PubMed ID: 32662096
[TBL] [Abstract][Full Text] [Related]
9. DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.
de Castro LF; Ovejero D; Boyce AM
Eur J Endocrinol; 2020 May; 182(5):R83-R99. PubMed ID: 32069220
[TBL] [Abstract][Full Text] [Related]
10. Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report.
Khadora M; Mughal MZ
Bone Rep; 2021 Dec; 15():101138. PubMed ID: 34660853
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic
Park PG; Park E; Hyun HS; Kang HG; Ha IS; Cho TJ; Ko JM; Cheong HI
Ann Clin Lab Sci; 2018 Sep; 48(5):665-669. PubMed ID: 30373874
[TBL] [Abstract][Full Text] [Related]
12. A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.
Merz LM; Buerger F; Ziegelasch N; Zenker M; Wieland I; Lipek T; Wallborn T; Terliesner N; Prenzel F; Siekmeyer M; Dittrich K
Front Endocrinol (Lausanne); 2022; 13():866831. PubMed ID: 35600592
[TBL] [Abstract][Full Text] [Related]
13. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
Avitan-Hersh E; Tatur S; Indelman M; Gepstein V; Shreter R; Hershkovitz D; Brick R; Bergman R; Tiosano D
J Clin Endocrinol Metab; 2014 Jan; 99(1):E132-6. PubMed ID: 24243633
[TBL] [Abstract][Full Text] [Related]
14. Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome.
Abebe L; Phung K; Robinson ME; Waldner R; Carsen S; Smit K; Tice A; Lazier J; Armour C; Page M; Dover S; Rauch F; Koujok K; Ward LM
Bone Rep; 2024 Mar; 20():101725. PubMed ID: 38229908
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
16. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
[TBL] [Abstract][Full Text] [Related]
17. Mosaic NRAS Q61R mutation in a child with giant congenital melanocytic naevus, epidermal naevus syndrome and hypophosphataemic rickets.
Ramesh R; Shaw N; Miles EK; Richard B; Colmenero I; Moss C
Clin Exp Dermatol; 2017 Jan; 42(1):75-79. PubMed ID: 27900779
[TBL] [Abstract][Full Text] [Related]
18. [Rare causes of Hypophosphatemia: diagnostic approach].
Trombetti A; Fokstuen S; Parvex P
Rev Med Suisse; 2023 Apr; 19(823):770-775. PubMed ID: 37133959
[TBL] [Abstract][Full Text] [Related]
19. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
Huynh C; Gillis A; Fazendin J; Abdullatif H
Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
